会议召开时间：2024 年 5 月 24 日（星期五）下午 15:00-17:00 证券代码：688151 证券简称：华强科技 公告编号：2024-025 湖北华强科技股份有限公司 关于参加 2023 年度科创板医疗设备集体业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2024 年 5 月 23 日（星期四）16:00 前通过电子邮件的方式将 需要了解和关注的问题提前发送至公司投资者关系邮箱 office@hqtc.com。公司 将在文字互动环节对投资者普遍关注的问题进行回答。 湖北华强科技股份有限公司（以下简称"公司"）已于 2024 年 4 月 27 日披 露公司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年度经 营成果、财务状况、发展理念，公司计划 ...

标题：关于湖北华强科技股份有限公司有关事项的监管工作函 证券代码：688151 证券简称：华强科技 监管类型：监管工作函 涉及对象：上市公司 处分日期：2024-05-13 处理事由：关于湖北华强科技股份有限公司有关事项的监管工作函 ...

2023 年年度股东大会会议资料 证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司 2023 年年度股东大会 会议资料 二〇二四年五月 | 湖北华强科技股份有限公司 | | 2023 年年度股东大会会议须知 | 1 | | --- | --- | --- | --- | | 湖北华强科技股份有限公司 | | 2023 年年度股东大会会议议程 | 4 | | 报告一： | | | 6 | | 独立董事 | 2023 | 年度述职报告（王广昌） | 6 | | 独立董事 | 2023 | 年度述职报告（刘洪川） | 15 | | 独立董事 | 2023 | 年度述职报告（刘景伟） | 24 | | 议案一 | ：2023 | 年度董事会工作报告 | 33 | | 议案二 | ：2023 | 年度监事会工作报告 | 50 | | 议案三 | ：2023 | 年年度报告全文及其摘要 | 55 | | 议案四 | ：2023 | 年度财务决算报告 | 56 | | 议案五 | ：2024 | 年度财务预算方案 | 63 | | 议案六 | ：2023 | 年度利润分配方案 | 65 | | 议案七 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 按照中国证监会《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》、上海证券交易所颁布的《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》及相关格式指引的要求，现将湖北华强科技股份 有限公司（以下简称"公司"或"华强科技"）2023 年度募集资金存放与实际使用情 况报告如下： 证券代码：688151 证券简称：华强科技 公告编号：2024-017 湖北华强科技股份有限公司 关于2023年度募集资金存放与实际使用情 况的专项报告 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意湖北华强科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2021]3368 号）同意注册，公司向社会公众公 开发行人民币普通股（A 股）8,620.62 万股，每股面值人民币 1 元，每股发行价 为人民币 35.09 元，募集资金总额为人民币 3,024,975,558.00 元，扣除发行费用 （不含增值税）人民 ...

Financial Performance - Total operating revenue for 2023 was corrected to ¥57,275.31 million, a decrease of 2.21% from the previous year's ¥58,567.94 million[1]. - Operating profit was revised to ¥477.45 million, reflecting a significant decline of 92.52% compared to ¥6,387.20 million in the prior year[1]. - Total profit was adjusted to ¥414.26 million, down 93.41% from ¥6,287.89 million year-over-year[1]. - Net profit attributable to shareholders was corrected to ¥792.51 million, an 88.36% decrease from ¥6,807.26 million in the previous year[1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was revised to -¥7,602.74 million, a drastic change from -¥1,292.02 million in the prior year, indicating a decline of 488.44%[1]. - Basic earnings per share remained at ¥0.02, down 90% from ¥0.20 in the previous year[1]. - Total assets at the end of the reporting period were corrected to ¥505,164.53 million, a decrease of 2.13% from ¥516,166.15 million at the beginning of the period[1]. Regulatory and Compliance Issues - The company received regulatory warnings from the Hubei Securities Regulatory Bureau and the Shanghai Stock Exchange regarding the need for corrections in previous financial reports[4]. - The company expressed sincere apologies to investors for the impact of the earnings report correction[7]. - The board will enhance supervision and training on financial accounting standards to improve the quality of financial information[8].

2023 年年度报告 公司代码：688151 公司简称：华强科技 湖北华强科技股份有限公司 2023 年年度报告 1 / 258 2023 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 □是 √否 三、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告"第三节 管理层讨论与分析"之"四、风险因素"。 四、 公司全体董事出席董事会会议。 五、 天职国际会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、 公司负责人孙光幸、主管会计工作负责人孙岩及会计机构负责人（会计主管人员）黄磊声 明：保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司于2024年4月25日召开第二届董事会第六次会议通过了《2023年度利润分配方案》，经天 职国际会计师事务所（特殊普通合伙）审计，截至2023年12月31日，公司期末合并 ...

2021 年年度报告 公司代码：688151 公司简称：华强科技 湖北华强科技股份有限公司 2021 年年度报告 1 / 209 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 □是 √否 三、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告"第三节 管理层讨论与分析"之"四、风险因素"。 四、 公司全体董事出席董事会会议。 五、 大信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、 公司负责人孙光幸 、主管会计工作负责人孙岩及会计机构负责人（会计主管人员）王德彬声 明：保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司于2022年3月25日召开第一届董事会第十五次会议通过了《关于2021年度利润分配方案的 议案》。经大信会计师事务所（特殊普通合伙）审计，截至2021年12月31日，母公 ...

Financial Performance - The company reported a net profit attributable to shareholders of RMB 68,072,565.20 for the year 2022, with a cash dividend payout ratio of 38.31%[5]. - The company's operating revenue for 2022 was ¥585,679,394.08, a decrease of 54.05% compared to ¥1,274,716,156.37 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥68,072,565.20, down 78.67% from ¥319,190,437.72 in 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,920,211.20, a decline of 104.76% compared to ¥271,684,550.93 in 2021[21]. - The net cash flow from operating activities decreased by 138.38%, resulting in -¥181,302,862.18 for 2022[24]. - The gross profit margin for the main business was 19.84%, a decrease of 22.86 percentage points year-on-year[78]. - The revenue from military products decreased by 49.97% year-on-year due to delays in military procurement plans[80]. - The company reported a large accounts receivable balance of CNY 638.89 million, accounting for 14.71% of current assets[78]. - The company’s main business revenue for the reporting period was 534.28 million RMB, a decrease of 57.60% year-on-year[89]. - The net cash flow from investment activities decreased by 2,018.34% year-on-year, primarily due to investments in structured deposits[87]. Dividend Policy - As of December 31, 2022, the total distributable profit was RMB 254,046,178.44, with a proposed cash dividend of RMB 0.757 per share (before tax) based on a total share capital of 344,500,000 shares[5]. - The company plans to maintain the total dividend amount even if there are changes in total share capital before the dividend distribution date, adjusting the per-share distribution accordingly[5]. - The company maintains a cash dividend policy that requires at least 20% of the distributable profit to be allocated as cash dividends, barring special circumstances[180]. - The company emphasizes a stable and continuous profit distribution policy, balancing investor returns with sustainable development[179]. - The board of directors is responsible for discussing and proposing the profit distribution plan, which must be approved by the shareholders' meeting[180]. Risk Management - The company has outlined various operational risks and corresponding mitigation strategies in the report, emphasizing the importance of risk management[4]. - The company has confirmed that there are no violations of decision-making procedures regarding external guarantees, ensuring compliance with regulations[8]. - The company faced significant revenue declines due to delays in military equipment orders and a drop in demand for vaccine-related products[24]. - The company is at risk of losing its competitive edge if it fails to invest adequately in R&D or if new product development cycles are too long[75]. - The company faces risks of order delays in special protective equipment due to the postponement of the "14th Five-Year" procurement plan[72]. Research and Development - The company's R&D investment as a percentage of operating revenue increased by 6.72 percentage points to 11.34% in 2022[23]. - The total R&D investment for the year was approximately ¥66.39 million, representing a 12.68% increase from the previous year, and accounting for 11.34% of total revenue[59]. - The number of R&D personnel increased to 139, making up 19.58% of the total workforce, compared to 17.96% in the previous year[65]. - The company has developed 15 core technologies, including integrated design technology for respiratory devices and early warning models for filter canister failure[55]. - The company is actively involved in research and development for next-generation military equipment, contributing to the modernization of national defense capabilities[47]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance, indicating a standard governance structure[6]. - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal requirements and maintaining effective governance[137]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards and effective decision-making[137]. - The supervisory board has held five meetings, ensuring compliance and protecting the rights of the company and its shareholders[138]. - The company established an internal control system to enhance risk prevention and operational standards[139]. Market and Industry Trends - The special protection industry is experiencing rapid growth due to increasing defense budgets and the rising demand for advanced equipment in response to nuclear and biochemical threats[45]. - The global pharmaceutical market is expected to exceed $150 billion by 2025, driven by population growth and aging demographics[48]. - The pharmaceutical packaging industry is expected to grow due to the increasing health awareness and aging population in China, providing significant opportunities for the upstream packaging materials sector[126]. - The market for nuclear and biochemical safety equipment is projected to grow due to increased demand from emergency response organizations and policy support[123]. - The competitive landscape in the military supplies industry is intensifying as more companies enter the market following the reduction of entry barriers[124]. Strategic Initiatives - The company is focusing on digital transformation with a "1331" action plan, aiming for a systematic approach to enhance digital capabilities and support the transition to smart factories[37]. - The company is committed to building an independent innovation system and increasing R&D investment to enhance its technological capabilities[129]. - The company is actively expanding into civilian markets, including medical packaging and medical devices, leveraging its technological advantages[68]. - The company plans to enhance its supply chain efficiency, aiming for a 15% reduction in operational costs by the next fiscal year[152]. - The company is committed to enhancing investor communication through various channels, including performance briefings and interactive platforms[139].

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[13]. - The company has set a revenue guidance of RMB 1.2 billion for the full year 2022, reflecting an expected growth of 10%[13]. - The company reported a total operating revenue of CNY 343.65 million for the first half of 2022, a decrease of 44.23% compared to the same period last year[19]. - Net profit attributable to shareholders was CNY 96.73 million, down 49.35% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 44.11 million, a decline of 74.13%[22]. - The company's gross profit margin was 28.69%, a decrease of 15.43 percentage points year-on-year, with the main business gross margin at 29.23%, down 15.47 percentage points[22]. - The net cash flow from operating activities was -CNY 130.30 million, a decrease of 313.38% compared to the previous year, primarily due to reduced cash receipts from sales and increased cash payments for raw materials[22]. - The company achieved a 38.37% increase in revenue and an 88.18% increase in sales for medical masks and protective clothing during the reporting period[33]. - The company reported a total operating revenue for the first half of 2022 of CNY 343,645,910.88, a decrease of 44.2% compared to CNY 616,130,514.48 in the same period of 2021[181]. - Net profit for the first half of 2022 was CNY 96,731,172.12, a decline of 49.3% from CNY 190,977,291.94 in the same period of 2021[182]. Research and Development - The company is investing RMB 50 million in R&D for new technologies aimed at enhancing product safety and effectiveness[13]. - The company's R&D expenditure accounted for 10.10% of operating revenue, an increase of 6.68 percentage points compared to the same period last year[21]. - R&D investment totaled approximately ¥34.7 million, a 64.80% increase compared to the previous year, with R&D expenses accounting for 10.10% of total revenue[39]. - The company filed 23 new patent applications during the reporting period, bringing the total authorized patents to 153[35]. - Key projects in core technology research, such as spherical activated carbon and failure warning technology, made effective progress, laying a solid foundation for new product development[29]. - The company has established long-term collaborations with various research institutions and universities to enhance its R&D capabilities[49]. Market Expansion and Product Development - User data indicates a growth in active users by 20% compared to the same period last year, reaching 1.2 million active users[13]. - New product launches include three innovative personal protective equipment (PPE) lines, which are expected to contribute an additional RMB 100 million in revenue by year-end[13]. - The company is actively expanding into the pharmaceutical packaging and medical device markets, leveraging its technological advantages[26]. - The company is focusing on expanding the market for non-COVID vaccine stoppers and promoting new products like rubber components for pre-filled syringes[33]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a budget of RMB 200 million allocated for this purpose[13]. Financial Management and Investments - The company raised a total of ¥3.025 billion in funds, with a net amount of ¥2.812 billion after deducting issuance costs[147]. - The company committed to invest ¥772 million in the new emergency rescue equipment production base project, with a cumulative investment of ¥9.08 million, representing 1.18% of the total commitment[147]. - The company allocated ¥353 million for the construction of a new protective material research platform, with a cumulative investment of ¥868,030, accounting for 0.25% of the total commitment[148]. - The company has not yet defined the investment direction for the remaining raised funds of ¥761.951 million[148]. - The company approved the use of raised funds to replace pre-invested project funds and issuance expenses totaling RMB 29,912,991.66[150]. Shareholder and Corporate Governance - The board has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[7]. - The company has established employee stock ownership platforms to enhance employee engagement and retention[163]. - The company has committed to various share restrictions for its major shareholders and key personnel, with terms ranging from 12 to 42 months[82]. - The company will prioritize cash dividends over stock dividends, ensuring a stable and continuous profit distribution policy[118]. - The controlling shareholder commits to avoiding any substantial competition with the company and will not provide confidential business information to competitors[121]. Risks and Challenges - The company has identified several key risks, including supply chain disruptions and regulatory changes, which may impact future performance[4]. - The company is facing risks related to core competitiveness, including potential delays in product orders and competition from foreign brands in the pharmaceutical packaging sector[57]. - The company’s performance is influenced by macroeconomic factors, market conditions, and changes in military procurement needs, which could affect future revenue[58]. Environmental and Social Responsibility - The management highlighted a focus on sustainability initiatives, aiming to reduce production waste by 25% by the end of 2022[13]. - The company has implemented real-time monitoring of wastewater discharge as part of its environmental responsibility efforts[79]. - The company provided assistance of 185,400 yuan for consumption support and 600,000 yuan in aid to Yanshan County during the reporting period[80].

Financial Corrections - The company corrected its financial reports for 2021, 2022, and the first half of 2023 due to insufficient revenue recognition, inadequate inventory impairment provisions, and cross-period cost issues, affecting revenue, costs, and profits without changing the overall profit or loss nature[2][3][13]. - For the 2021 annual report, the company reduced accounts receivable and revenue by CNY 526,460.17, adjusted net profit down by CNY 1,031,377.67, and decreased retained earnings by CNY 928,239.90[6][13]. - In the 2022 annual report, the company adjusted revenue down by CNY 23,727,654.87 and reduced net profit by CNY 4,361,070.62, while also increasing inventory impairment losses by CNY 12,492,262.60[9][10][13]. - The adjustments resulted in a net profit impact of -CNY 103.14 million for 2021, +CNY 103.14 million for the first half of 2022, -CNY 436.11 million for 2022, and -CNY 64.84 million for the first half of 2023[13]. Financial Metrics Adjustments - The company's accounts receivable decreased by CNY 500,137.16 to CNY 605,029,206.66 as a result of the corrections[15]. - Inventory increased by CNY 526,460.17 to CNY 181,744,196.07 following the adjustments[15]. - The company’s deferred tax assets were adjusted by CNY 16,086.12, resulting in a new total of CNY 26,508,653.00[15]. - The adjustments to accounts payable increased by CNY 1,073,786.80, bringing the total to CNY 329,525,531.34[15]. - The company's total revenue for the fiscal year 2021 was adjusted to approximately CNY 1,274.72 million, reflecting a decrease of 0.04% due to corrections[16]. - For the first half of 2022, the adjusted revenue was CNY 343.65 million, an increase of 0.15% compared to the previous figure[18]. - The net profit for the fiscal year 2022 was revised to CNY 68.07 million, showing a decrease of 6.02% after adjustments[21]. - As of June 30, 2023, the company's total assets were reported at approximately CNY 5,080.50 million, reflecting a slight increase of 0.03%[24]. - The adjusted net profit for the first half of 2023 was CNY 28.32 million, a decrease of 2.24% compared to the previous figure[24]. - The company's total liabilities as of December 31, 2022, were adjusted to CNY 376.72 million, reflecting a minor increase of 0.18%[21]. - The adjusted gross profit margin for the fiscal year 2022 was reported at 26.0%, indicating a decrease from the previous year[21]. - The company experienced a significant increase in asset impairment losses, with a correction showing a decrease of 454.65% for the fiscal year 2022[21]. Project Investments - The cumulative investment in the "New Type Nuclear Biological Emergency Rescue Protective Equipment Industrialization Production Base" project was adjusted to ¥21,934,822.38, with a progress rate of 2.84%[26]. - The cumulative investment in the "New Type Nuclear Biological Protective Basic Material R&D Platform Construction Project" was adjusted to ¥1,341,866.00, with a progress rate of 0.38%[26]. Management and Compensation - The total remuneration for key management personnel was corrected to ¥697.56 million for the current period, up from ¥603.19 million[28]. - The total remuneration for non-independent directors and supervisors was disclosed as ¥943,700 in the 2022 annual report[28]. - The company reported additional related party transactions totaling ¥1,566,379.33 for employee compensation with China Weapon Equipment Group Co., Ltd.[29]. Compliance and Future Measures - The audit committee confirmed that the corrections made to the financial reports comply with relevant accounting standards and accurately reflect the company's financial status[31]. - The supervisory board agreed that the corrections to the financial data do not harm the interests of the company and its shareholders[32]. - The accounting firm confirmed that the company's handling of the accounting errors aligns with the applicable accounting standards[33]. - The company plans to enhance supervision and training on financial accounting practices to prevent future issues[34]. - The company expressed apologies for any inconvenience caused to investors due to the financial reporting errors[34].